Nitesh Dave of Biocon joined us for World Biosimilar Congress USA 2016 to discuss what happens to biosimilars being developed under 505b (2).
Download this presentation to understand more about:
- Key features of 505b (2)
- Key features of 351k (1, 2)
- Products approved under 505b (2)
- Path ahead for products under development
Get your copy here!
If you’re interested in learning more about biosimilars being developed, join us for World Biosimilar Congress USA 2017 , held May 23-24 in San Diego, CA . This event is co-located with Americas Antibody Congress and Cell Culture World Congress USA.